In Vivo Comparison of the Phenotypic Aspects and Molecular Mechanisms of Two Nephrotoxic Agents, Sodium Fluoride and Uranyl Nitrate.


Journal

International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455

Informations de publication

Date de publication:
29 03 2019
Historique:
received: 20 02 2019
revised: 22 03 2019
accepted: 26 03 2019
entrez: 3 4 2019
pubmed: 3 4 2019
medline: 15 8 2019
Statut: epublish

Résumé

Because of their nephrotoxicity and presence in the environment, uranium (U) and fluoride (F) represent risks to the global population. There is a general lack of knowledge regarding the mechanisms of U and F nephrotoxicity and the underlying molecular pathways. The present study aims to compare the threshold of the appearance of renal impairment and to study apoptosis and inflammation as mechanisms of nephrotoxicity. C57BL/6J male mice were intraperitoneally treated with a single dose of U (0, 2, 4 and 5 mg/kg) or F (0, 2, 5, 7.5 and 10 mg/kg) and euthanized 72 h after. Renal phenotypic characteristics and biological mechanisms were evaluated by urine biochemistry, gene/protein expression, enzyme activity, and (immuno)histological analyses. U and F exposures induced nephrotoxicity in a dose-dependent manner, and the highest concentrations induced severe histopathological alterations as well as increased gene expression and urinary excretion of nephrotoxicity biomarkers. KIM-1 gene expression was induced starting at 2 mg/kg U and 7.5 mg/kg F, and this increase in expression was confirmed through in situ detection of this biomarker of nephrotoxicity. Both treatments induced inflammation as evidenced by cell adhesion molecule expression and in situ levels, whereas caspase 3/7-dependent apoptosis was increased only after U treatment. Overall, a single dose of F or U induced histopathologic evidence of nephrotoxicity renal impairment and inflammation in mice with thresholds under 7.5 mg/kg and 4 mg/kg, respectively.

Identifiants

pubmed: 30934888
pii: ijerph16071136
doi: 10.3390/ijerph16071136
pmc: PMC6479911
pii:
doi:

Substances chimiques

Biomarkers 0
Havcr1 protein, mouse 0
Hepatitis A Virus Cellular Receptor 1 0
Uranyl Nitrate 0C0WI17JYF
Sodium Fluoride 8ZYQ1474W7
Casp3 protein, mouse EC 3.4.22.-
Casp7 protein, mouse EC 3.4.22.-
Caspase 3 EC 3.4.22.-
Caspase 7 EC 3.4.22.-

Types de publication

Comparative Study Journal Article

Langues

eng

Références

Anticancer Res. 2017 Sep;37(9):4767-4777
pubmed: 28870895
Chem Biol Interact. 2010 Nov 5;188(2):319-33
pubmed: 20650267
Environ Toxicol. 2011 Feb;26(1):86-92
pubmed: 19852076
J Clin Invest. 2008 May;118(5):1657-68
pubmed: 18414680
J Nutr Biochem. 2012 May;23(5):494-500
pubmed: 21684138
Health Phys. 2008 Feb;94(2):170-9
pubmed: 18188051
Toxicol Sci. 2007 Aug;98(2):479-87
pubmed: 17522072
Int Arch Occup Environ Health. 2000 Jun;73 Suppl:S90-2
pubmed: 10968567
Ren Fail. 2016 Jun;38(5):770-5
pubmed: 26984368
Toxicol Sci. 2007 Aug;98(2):458-68
pubmed: 17566059
Arch Toxicol. 2017 Apr;91(4):1903-1914
pubmed: 27585666
Toxicol Sci. 1998 May;43(1):68-77
pubmed: 9629621
Health Phys. 2006 Feb;90(2):139-47
pubmed: 16404171
Nephrol Dial Transplant. 2009 Nov;24(11):3265-8
pubmed: 19318357
Nat Biotechnol. 2010 May;28(5):478-85
pubmed: 20458318
J Appl Toxicol. 2003 Nov-Dec;23(6):437-46
pubmed: 14635268
Fish Shellfish Immunol. 2017 Apr;63:314-321
pubmed: 28223109
J Clin Invest. 2015 Apr;125(4):1620-36
pubmed: 25751064
J Gerontol. 1957 Jan;12(1):14-9
pubmed: 13398599
Am J Physiol Renal Physiol. 2016 May 1;310(9):F872-84
pubmed: 26823281
Basic Clin Pharmacol Toxicol. 2014 Mar;114(3):271-80
pubmed: 24330236
Braz J Med Biol Res. 2007 Jun;40(6):857-65
pubmed: 17581686
Arch Toxicol. 1998;72(2):104-9
pubmed: 9456082
BMC Genomics. 2006 Jan 11;7:2
pubmed: 16405725
Toxicol Appl Pharmacol. 2015 Sep 15;287(3):306-15
pubmed: 26148447
Nephrol Dial Transplant. 2016 Aug;31(8):1243-50
pubmed: 26175143
Virchows Arch. 2003 Aug;443(2):206-16
pubmed: 12811555
Am J Physiol Renal Physiol. 2009 Jul;297(1):F200-9
pubmed: 19369290
Proc Soc Exp Biol Med. 1992 Jan;199(1):93-6
pubmed: 1728043
Toxicol Lett. 2005 Dec 30;160(1):69-75
pubmed: 16043314
Biol Trace Elem Res. 2001 Winter;84(1-3):139-54
pubmed: 11817685
Virchows Arch B Cell Pathol Incl Mol Pathol. 1982;41(1-2):181-92
pubmed: 6190305
Radiat Res. 2017 Jan;187(1):107-127
pubmed: 28036235
Toxicology. 2008 Jan 20;243(3):340-7
pubmed: 18069112
Toxicol Sci. 2006 Jan;89(1):287-95
pubmed: 16221956
Histochem J. 1975 Jul;7(4):343-55
pubmed: 1150482
Arch Toxicol. 2018 Nov;92(11):3277-3289
pubmed: 30225638
Biol Trace Elem Res. 2013 Jun;152(3):367-72
pubmed: 23400904
EMBO J. 2015 Oct 1;34(19):2441-64
pubmed: 26282792
Arch Toxicol. 2011 Apr;85(4):327-35
pubmed: 20859737
Mediators Inflamm. 2009;2009:137072
pubmed: 20182538
Toxicol Appl Pharmacol. 2013 Nov 1;272(3):888-94
pubmed: 23933529
Toxicol Pathol. 2007 Dec;35(7):1000-9
pubmed: 18098045
Free Radic Res. 2014 Oct;48(10):1218-31
pubmed: 25056594
Toxicol Sci. 2010 Dec;118(2):324-47
pubmed: 20554698
Am J Physiol Renal Physiol. 2010 Jun;298(6):F1472-83
pubmed: 20181666
J Dent. 2005 Mar;33(3):177-86
pubmed: 15725518
Toxicology. 2011 Jan 11;279(1-3):27-35
pubmed: 20849911
Arch Toxicol. 2011 Nov;85(11):1441-52
pubmed: 21340527
Am J Physiol Lung Cell Mol Physiol. 2001 Dec;281(6):L1472-83
pubmed: 11704544
Environ Res. 2007 Jan;103(1):112-6
pubmed: 16834990
Toxicol Lett. 2006 Dec 1;167(2):152-61
pubmed: 17069995
Proc Soc Exp Biol Med. 1979 Jan;160(1):99-103
pubmed: 419135
J Am Soc Nephrol. 1998 Jan;9(1):33-7
pubmed: 9440084
World J Nephrol. 2012 Aug 6;1(4):92-9
pubmed: 24175246

Auteurs

Alice Bontemps (A)

Institut de Radioprotection et de Sûreté Nucléaire (IRSN), PSE-SANTE/SESANE/LRTOX, 92262 Fontenay-aux-Roses, France . alice.bontemps@irsn.fr.

Laurine Conquet (L)

Institut de Radioprotection et de Sûreté Nucléaire (IRSN), PSE-SANTE/SESANE/LRTOX, 92262 Fontenay-aux-Roses, France . laurine.conquet54@gmail.com.

Christelle Elie (C)

Institut de Radioprotection et de Sûreté Nucléaire (IRSN), PSE-SANTE/SESANE/LRTOX, 92262 Fontenay-aux-Roses, France . christelle.elie@irsn.fr.

Victor Magneron (V)

Institut de Radioprotection et de Sûreté Nucléaire (IRSN), PSE-SANTE/SESANE/LRTOX, 92262 Fontenay-aux-Roses, France . victor.magneron-manpower@irsn.fr.

Céline Gloaguen (C)

Institut de Radioprotection et de Sûreté Nucléaire (IRSN), PSE-SANTE/SESANE/LRTOX, 92262 Fontenay-aux-Roses, France . celine.gloaguen@irsn.fr.

Dimitri Kereselidze (D)

Institut de Radioprotection et de Sûreté Nucléaire (IRSN), PSE-SANTE/SESANE/LRTOX, 92262 Fontenay-aux-Roses, France . dimitri.kereselidze@irsn.fr.

Karine Tack (K)

Institut de Radioprotection et de Sûreté Nucléaire (IRSN), PSE-SANTE/SESANE/LRTOX, 92262 Fontenay-aux-Roses, France . Karine.TACK@asn.fr.

Olivier C Barbier (OC)

Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional, Departamento de Toxicología, Av. IPN No. 2508 Col., San Pedro Zacatenco, México City, CP 07360, Mexico. obarbier@cinvestav.mx.

Yann Guéguen (Y)

Institut de Radioprotection et de Sûreté Nucléaire (IRSN), PSE-SANTE/SESANE/LRTOX, 92262 Fontenay-aux-Roses, France . yann.gueguen@irsn.fr.
Institut de Radioprotection et de Sûreté Nucléaire (IRSN), PSE-SANTE/SESANE/LRSI, 92262 Fontenay-aux-Roses, France. yann.gueguen@irsn.fr.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH